Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up study.
Konrad RejdakEwa PapućPublished in: European journal of neurology (2021)
Cladribine was safe in NMOSD patients over a 2-year observation period. Cladribine treatment was associated with clinical stabilization, as evidenced by significantly decreased ARR and no progression of EDSS score.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- spectrum disorder
- rheumatoid arthritis patients
- chronic kidney disease
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- signaling pathway
- prognostic factors
- juvenile idiopathic arthritis
- peritoneal dialysis
- replacement therapy